Tiffany Randle
Family · Amarillo, TXNPI 1124301197
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by EMD Serono, Inc. at 52.0% of the total. Reporting peaked in 2022 at $16,591 and has fallen 98.3% since, to $278 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 803 payments — averaging $62.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$26K
- AbbVie$7K
- Livanova USA, Inc.$5K
- Boston Scientific$3K
- Abbott$1K
- Bristol Myers Squibb$813
- plus $9K from 43 others
What the payments were for
- Speaking & faculty fees$24,58049%
- Travel & lodging$11,33323%
- Food & beverage$14,02328%
- Education$2971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$24,497
- Duopa$4,459
- VNS Therapy$2,962
- VERCISE$2,596
- VNS - Sentiva$1,545
- ZEPOSIA$688
- Infinity DBS Pulse Generators$598
- PERCEPT PC BRAINSENSE$379
- INFINITY$223
How this compares
$50,233 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 149 | $243,881 |
| NuplazidPimavanserin Tartrate | 31 | $190,825 |
| IngrezzaValbenazine Tosylate | 24 | $145,554 |
| Kesimpta PenOfatumumab | 12 | $97,084 |
| QuliptaAtogepant | 69 | $84,772 |
| RytaryCarbidopa/Levodopa | 76 | $81,216 |
| Aimovig AutoinjectorErenumab-Aooe | 62 | $52,635 |
| Nurtec OdtRimegepant Sulfate | 44 | $51,047 |
| LamictalLamotrigine | 28 | $45,182 |
| XcopriCenobamate | 37 | $40,057 |
| NeuproRotigotine | 36 | $36,319 |
| Emgality PenGalcanezumab-Gnlm | 47 | $35,390 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 34 | $32,890 |
| VimpatLacosamide | 28 | $30,697 |
| KeppraLevetiracetam | 15 | $27,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Neupro, Vimpat | $273 | $310,898213 claims |
| Acadia Pharmaceuticals IncNuplazid | $14 | $190,82531 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $698 | $164,08943 claims |
| AbbVieQulipta, Ubrelvy | $6,561 | $108,14283 claims |
| Amneal Pharmaceuticals LLCRytary | $119 | $81,21676 claims |
| PfizerNurtec Odt | $288 | $51,04744 claims |
| SK Life Science, Inc.Xcopri | $409 | $40,05737 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $21,36812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $78 | $16,52924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Amarillo
- Kyla BeedyAmarillo$54K
- Cory PickettAmarillo$34K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.